SGLT2 Inhibitors

Question 1

What medications are part of the SGLT2 inhibitor class

Answer 1

• CanagliFLOZIN (Invokana)
• DapagliFLOZIN (Farxiga)
• EmpagliFLOZIN (Jardiance)

Question 2

What is the MOA of SGLT2 Inhibitors

Answer 2

Block the reabsorption of glucose in the kidneys
- promotes excretion of glucose in the urine

Question 3

True or false:

SGLT-2 inhibitors may be used in monotherapy or in combination with other drugs

Answer 3

True

Is approved for monotherapy (although Dr. Busti doesn’t like it…)

Question 4

True or false:

SGLT-2 Inhibitors are not highly bound to albumin

Answer 4

False: may be up to 99% bound to albumin

Question 5

Patients taking SGLT2 inhibitors have a ________ risk of diabetic infections and amputations

Answer 5

INCREASED by up to 2x!
- Black box warning for canagliflozin

Question 6

Why is there an increased risk for UTI and genital mycotic infections for patients taking SGLT-2 infections?

Answer 6

Increased glucose concentrations in the urine make a nice environment for bacteria to grow

Question 7

True or false:

SGLT-2 inhibitors do not appear to worsen the progression of beta-cell burnout

Answer 7

True - there is no pancreatic stimulation with these agents

Question 8

Why is there an increased risk for volume depletion and hypotension in patients who take SGLT-2 inhibitors?

Answer 8

The increased excretion of glucose into the urine causes water to follow (diuretic effect)

Question 9

SGLT-2 inhibitors may decrease A1C by up to 1%, but only________ of patients reach goal of <7%

Answer 9

1/3, 33%